Tetra Bio Pharma Inc
F:JAM1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its Industry Average (1.5), the stock would be worth €0 (100% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | €0.08 |
0%
|
| Industry Average | 1.5 | €0 |
-100%
|
| Country Average | 2.9 | €0 |
-100%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Tetra Bio Pharma Inc
F:JAM1
|
10.6m EUR | 0 | -0.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 12.7 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 5.7 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 4.9 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 4.9 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 4.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.8 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 2.4 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 2.4 | 16.6 |
Market Distribution
Other Multiples
Tetra Bio Pharma Inc
Glance View
Tetra Bio-Pharma, Inc. engages in the discovery and development of cannabinoid-based drugs and treatments. The company is headquartered in Orleans, Ontario and currently employs 33 full-time employees. The company went IPO on 2008-04-15. The firm is engaged in the development of bio pharmaceuticals and natural health products containing cannabis and other medicinal plant-based elements. The firm is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. The firm's objective is to bring prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acute Respiratory Distress Syndrom (ARDS), sepsis and ophthalmic disease. Its products include QIXLEEF, CAUMZ, REDUVO Capsules, REDUVO Adversa, ARDS-003 and PPP-002. Its QIXLEEF is a botanical inhaled drug with a fixed ratio of tetrahydrocannabinol (THC) and cannabidiol (CBD).
